Pag-aaral pangklinika para sa Melanoma sa Oklahoma
14 pag-aaral para sa Melanoma ang naghahanap ng mga kalahok sa mga site sa Oklahoma.
Mga Lungsod sa Oklahoma
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06246916Pan-tumor MRD Study
- Oklahoma Cancer Specialists and Research Institute (OCSRI), Tulsa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 3
Edad 75 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07068074A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04511013Project: Every Child for Younger Patients With Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT07327489Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Retina Consultants of Oklahoma, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT07015190Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Oklahoma City, Oklahoma City
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- OU Health Stephenson Cancer Center, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 25, 2026 · NCT05549297SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774BostonGene and Exigent Genomic INsight Study
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 17, 2025 · NCT06272864Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- OUHSC Stephenson Cancer Center, Oklahoma City
- Mercy Health Center - Oncology Hematology, Oklahoma City
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 27, 2024 · NCT03860883Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.